Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With Migraine

Inclusion Criteria: Healthy participants (Phase 1 of enrolment): * Age 18 to 65 years * No functional or structural vestibular disorder * No history of unilateral or bilateral vestibulopathy * No diagnosis of migraine * Written informed consent provided by the participant Participants with migraine (Phase 2 of enrolment): * Diagnosis of episodic or chronic migraine according to the ICHD-3 criteria * Age 18 to 65 years * No functional or structural vestibular disorder * No history of unilateral or bilateral vestibulopathy * Written informed consent provided by the participant Exclusion Criteria: * Hypersensitivity to atogepant * Intake of any CGRP-antagonist medication within the last 6 months * Known impaired kidney function with a creatinine clearance below 30 mL/min, or known impaired liver function (Child-Pugh B or C) * Insufficiently controlled, unstable or newly diagnosed cardiovascular disease, for example ischaemic coronary disease, coronary vasospasm or cerebral ischaemia * Myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, cardiac surgery, stroke of any kind or transient ischaemic attack within the last 6 months (24 weeks) * Medication overuse headache * Cardiac pacemaker or other implanted electronic device * Concomitant use of strong CYP3A4 inhibitors, of strong or moderate CYP3A4 inducers, or of OATP1B1/OATP1B3 inhibitors * Pregnancy or breastfeeding; women of childbearing potential not using effective contraception during the study * Participation in another clinical trial with an investigational medicinal product within 30 days before the screening visit * Inability to understand the participant information or to give written informed consent